What is the study about? In 2017 the hepatitis B vaccine was added to the UK routine immunisation programme in the form of the ‘6-in-1’ vaccine, immunising against diphtheria, tetanus, pertussis (whooping cough), poliovirus, Haemophilus influenzae b and hepatitis B virus. There are currently two licensed 6-in-1 vaccines called Infanrix hexa (6 in 1(IH)) and Vaxelis (6 in 1(V)). 6 in 1(IH) is currently used routinely in the UK.

You are invited to take part in a study to investigate typhoid fever and how the typhoid bacteria causes disease.  The study is being run by the Oxford Vaccine Group which is part of the University of Oxford.

If you are aged 18 to 60 years old, in good health and live in the Oxford area, then you may be eligible to take part in the study. We will provide reimbursement for your time, inconvenience and travel. The total study participation time is 6 months.

Background

Understanding RSV: Severe disease and the long term consequences

Oxford Vaccine Group are inviting volunteers to take part in a study to help us learn more about the virus that most commonly causes coughs, colds and chest infections in young children, and sometimes causes children to be so unwell they have to be admitted to hospital.

Some facts about RSV disease (respiratory syncytial virus):

The Oxford Vaccine Group is recruiting infants aged 4 – 7 months to a type 1 diabetes prevention trial. POInT (Primary Oral Insulin Trial) is recruiting infants who were screened for diabetes at birth through the INGR1D Study and have been found to be at high risk for developing diabetes.

The Oxford Vaccine Group are inviting students in school year 12 to take part in a research project to understand whether immunising teenagers with vaccines against ‘Meningitis B’ could protect them and the rest of the community against these potentially deadly bacteria. This is a national study involving 24 000 year 12 students across the United Kingdom.  Teenagers at participating schools are being asked to take part by local research teams involved.

You are invited to take part in a study to investigate a new Vaccine Against Meningitis B in Oxford (VAMBOX). The study is being run by the Oxford Vaccine Group at the University of Oxford.

If you are 18 to 50 yrs old and are in good health, then you may be eligible to take part in the study. We will provide reimbursement for your time, inconvenience and travel. Participants will receive up to £630.00 if they remain in the study for the entire period. The total study participation time is 12 months.

Background

Some facts about RSV disease (respiratory syncytial virus):

RSV is a virus;

• it causes coughs, colds and chest infections
• is responsible for around 1 in 6 hospital admissions for infants  in the UK
• The second largest worldwide cause of deaths in children between one month and 1 year of age, most are in Asia and Africa

What do we want to do?

We would like to identify 2000 babies from birth and follow them up to see if any become unwell with RSV disease

Are you a parent or guardian of a child aged 0-5 years?
You may be interested in taking part in a study about vaccine attitudes.
This study is run by Oxford Vaccine Group, part of the University of Oxford.

What is the study about?

We will be holding focus groups (discussions) with small groups of parents of children aged 0-5 years.

Welcome to the ‘nose swab’ study

This study will help us better understand pneumococcal carriage and disease.

To find out more about pneumococcal disease please visit the vaccine knowledge website. (http://vk.ovg.ox.ac.uk/pneumococcal-disease)

If you are interested in this study, the full information booklet is available HERE

The IgNiTE Study

A study testing a new treatment for children with encephalitis.

The Department of Paediatrics at the University of Oxford, in collaboration with NHS Trusts across the United Kingdom, is currently running a study for hospitalised children with encephalitis. The study will assess whether a treatment called intravenous immunoglobulin (IVIg, sometimes referred to as antibody treatment) has any benefit for these children when given early during the hospital admission.